Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROUD: Denosumab for Osteoporosis in Frail Elderly
NCT02753283Phase 4Completed
- Start
- Jun 2016
- Primary completion
- Aug 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of denosumab in osteoporosis (4 arms). Primary endpoints: Bone Density of the Total Hip at 24 months and Bone Density of the Spine at 24 months. Started Jun 2016; status: completed.
02
Drugs
denosumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT02753283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02753283.